|By Marketwired .||
|September 2, 2014 01:40 PM EDT||
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 09/02/14 -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in two investor conferences in September: the Annual Barrington Research Fall Investment Conference and the Rodman & Renshaw Annual Global Investment Conference.
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be available for one-on-one meetings with the investment community on September 3, 2014 at the Annual Barrington Research Fall Investment Conference taking place September 3 - 4, 2014 at the Four Seasons Hotel, in Chicago.
Mr. Berlin will also present a corporate overview at the Rodman & Renshaw Annual Global Investment Conference being held from September 8 - 10, 2014 at the New York Palace Hotel. Mr. Berlin's presentation is scheduled for September 10, 2014 at 3:20 p.m. The presentation will be webcast live and archived online at the Investors section of the Company's website at www.rosettagenomics.com.
About Rosetta Genomics
Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, the Cancer Origin Test improving the ability of physicians to accurately diagnose CUP, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Cancer Origin Test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Dec. 5, 2016 07:30 AM EST Reads: 7,029
Dec. 5, 2016 07:30 AM EST Reads: 958
Dec. 5, 2016 07:15 AM EST Reads: 1,250
Dec. 5, 2016 06:45 AM EST Reads: 1,790
Dec. 5, 2016 06:45 AM EST Reads: 1,590
Dec. 5, 2016 06:45 AM EST Reads: 972
Dec. 5, 2016 06:30 AM EST Reads: 692
Dec. 5, 2016 06:15 AM EST Reads: 859
Dec. 5, 2016 06:00 AM EST Reads: 1,678
Dec. 5, 2016 04:30 AM EST Reads: 5,214
Dec. 5, 2016 04:15 AM EST Reads: 1,614
Dec. 5, 2016 04:00 AM EST Reads: 5,406
Dec. 5, 2016 04:00 AM EST Reads: 5,115
Dec. 5, 2016 04:00 AM EST Reads: 4,701
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 5, 2016 03:30 AM EST Reads: 941